SB 43: HEALTH SERVICES: Provides relative to psychedelic-assisted therapy. (8/1/26) (EN INCREASE GF EX See Note)
SB 43 establishes Louisiana's Psychedelic-Assisted Therapy Program within the Department of Health to fund clinical studies using psychedelic medications (like psilocybin) for treating opioid use disorders, co-occurring substance use disorders, and treatment-resistant mental health conditions. The program requires academic health centers to meet strict federal and state compliance standards - including FDA approval, safety protocols, and therapist qualifications - to conduct these studies. Eligible patients, including those with the specified conditions, may participate, and parishes can use opioid settlement funds to enroll residents. The bill mandates annual progress reports from participating centers and requires coordination with other states conducting similar research. This is a research-focused program, not a policy allowing general therapeutic use.
















